Currently Viewing:
The International Society for Pharmacoeconomics and Outcomes Research
Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences
September 08, 2017
Dr Patricia Danzon: Learning From European Health Systems
August 30, 2017
Dr Ilene Hollin: One-Size-Fits-All to Value Doesn't Work
August 23, 2017
Dr Patricia Danzon Highlights European Examples of Restraining Drug Prices
August 16, 2017
Dr Ilene Hollin Outlines Differing Definitions of Value
August 09, 2017
Dr Patricia Danzon: Cost Effective Doesn't Mean Affordable
August 03, 2017
Dr Michael Sherman on Performance-Based Risk-Sharing Agreements
July 28, 2017
Dr David Cutler Assesses the Political Odds of Drug Pricing Reform
July 25, 2017
Dr Steve Pearson on Using Health Technology Assessment to Guide Decision Making
July 23, 2017
Dr Gail Wilensky: Increased Competition a Better Drug Pricing Solution Than Cost Controls
July 16, 2017
Dr Steve Pearson on Data Needed to Evaluate Clinical and Economic Effects of New Therapies
July 14, 2017
Dr David Cutler: Trump Administration's Attention Not on Value-Based Purchasing
July 09, 2017
Currently Reading
Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations
July 06, 2017
Dr Scott Ramsey Addresses the Need for Differential Pricing Structures for Drugs
July 02, 2017
Dr Gail Wilensky Raises Questions About Medicaid's Matching Grant Structure
June 25, 2017
Dr Steve Pearson Explains How ICER Price Benchmarks Align Cost With Patient Benefits
June 22, 2017
Dr David Cutler Discusses Opportunities for Bipartisan ACA Reform
June 20, 2017
Dr Scott Ramsey on Challenges of Determining Cost Effectiveness of Novel Cancer Treatments
June 19, 2017
Dr Steve Pearson's Outlook on the Ongoing Updates to ICER's Value Framework
June 18, 2017

Dr Gail Wilensky on the Likelihood of Continuing Value-Based Reimbursement Demonstrations

Value-based care strategies will continue to progress no matter who occupies the White House, according to Gail Wilensky, PhD, of Project HOPE. HHS Secretary Tom Price has indicated his support for limited demonstrations, but Wilensky predicts he will continue to push against large-scale mandatory demonstrations.


Value-based care strategies will continue to progress no matter who occupies the White House, according to Gail Wilensky, PhD, of Project HOPE. HHS Secretary Tom Price has indicated his support for limited demonstrations, but Wilensky predicts he will continue to push against large-scale mandatory demonstrations.

Transcript (slightly modified)

Do you think the country’s trajectory over the past few years toward value-based care will continue under the new administration?

I think we are on value-based care as where we need to be going forward, no matter who is running the administrations. We’re not quite as advanced as we like to talk about it. Most of the people who are doing value-based care strategies still reimburse their physicians using fee-for-service, which is not particularly compatible with value-based care, so we’re talking a little better game than we’re actually doing, but I don’t see us moving backward from where we are. It’s a question of how fast, how aggressively we’ll move forward to being really serious about purchasing value-based care.

What impact do you think HHS Secretary Tom Price, MD, will have on new payment model pilots?

The question about whether Dr Price, Secretary Price now, will pull back from pilots has been raised a lot. I think what he is likely to move away from are the mandatory demonstrations, which had been raised at the end of the Obama administration, and which have an appeal in that they don’t have to contend with self-selection as an issue. But I’m not sure they’re as critical as they’re sometimes made out to be.

His point, and I have some sympathy with this, is that by having large-scale, mandatory demonstrations, you’re basically taking away the right of Congress to make changes in reimbursement, and that, more than potentially limited mandatory demonstrations or voluntary demonstrations, is what he was pushing against, as well as the other Republican members of the Congress.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!